2023-05-01 2024-04-30 false Capium Accounts Production 1.1 11950275 2023-05-01 2024-04-30 11950275 bus:FullAccounts 2023-05-01 2024-04-30 11950275 bus:FRS102 2023-05-01 2024-04-30 11950275 bus:AuditExemptWithAccountantsReport 2023-05-01 2024-04-30 11950275 bus:SmallCompaniesRegimeForAccounts 2023-05-01 2024-04-30 11950275 bus:PrivateLimitedCompanyLtd 2023-05-01 2024-04-30 11950275 2023-05-01 2024-04-30 11950275 2024-04-30 11950275 bus:RegisteredOffice 2023-05-01 2024-04-30 11950275 core:WithinOneYear 2024-04-30 11950275 core:AfterOneYear 2024-04-30 11950275 1 2023-05-01 2024-04-30 11950275 bus:Director1 2023-05-01 2024-04-30 11950275 bus:Director1 2024-04-30 11950275 bus:Director1 2022-05-01 2023-04-30 11950275 2022-05-01 11950275 bus:LeadAgentIfApplicable 2023-05-01 2024-04-30 11950275 2022-05-01 2023-04-30 11950275 2023-04-30 11950275 core:WithinOneYear 2023-04-30 11950275 core:AfterOneYear 2023-04-30 11950275 bus:EntityAccountantsOrAuditors 2022-05-01 2023-04-30 11950275 bus:OrdinaryShareClass1 2023-05-01 2024-04-30 11950275 bus:OrdinaryShareClass1 2024-04-30 11950275 bus:OrdinaryShareClass1 2022-05-01 2023-04-30 11950275 bus:OrdinaryShareClass1 2023-04-30 11950275 core:PlantMachinery 2023-05-01 2024-04-30 11950275 core:PlantMachinery 2024-04-30 11950275 core:PlantMachinery 2023-04-30 11950275 core:MotorCars 2023-05-01 2024-04-30 11950275 core:MotorCars 2024-04-30 11950275 core:MotorCars 2023-04-30 11950275 core:FurnitureFittings 2023-05-01 2024-04-30 11950275 core:FurnitureFittings 2024-04-30 11950275 core:FurnitureFittings 2023-04-30 11950275 core:ComputerEquipment 2023-05-01 2024-04-30 11950275 core:ComputerEquipment 2024-04-30 11950275 core:ComputerEquipment 2023-04-30 11950275 core:LandBuildings 2023-05-01 2024-04-30 11950275 core:LandBuildings 2024-04-30 11950275 core:LandBuildings 2023-04-30 11950275 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2024-04-30 11950275 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2023-04-30 11950275 core:NetGoodwill 2023-05-01 2024-04-30 11950275 core:NetGoodwill 2024-04-30 11950275 core:NetGoodwill 2023-04-30 11950275 core:CostValuation core:Non-currentFinancialInstruments 2024-04-30 11950275 core:CostValuation core:Non-currentFinancialInstruments 2023-04-30 11950275 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2024-04-30 11950275 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2024-04-30 11950275 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2024-04-30 11950275 core:Non-currentFinancialInstruments 2024-04-30 11950275 core:Non-currentFinancialInstruments 2023-04-30 11950275 core:RetainedEarningsAccumulatedLosses 2024-04-30 11950275 core:RetainedEarningsAccumulatedLosses 2023-04-30 11950275 core:RetainedEarningsAccumulatedLosses 2023-05-01 11950275 core:RetainedEarningsAccumulatedLosses 2022-05-01 11950275 core:RetainedEarningsAccumulatedLosses 2023-05-01 2024-04-30 11950275 core:RetainedEarningsAccumulatedLosses 2022-05-01 2023-04-30 11950275 core:RetainedEarningsAccumulatedLosses 2024-04-30 11950275 core:RetainedEarningsAccumulatedLosses 2023-04-30 11950275 dpl:Item1 2023-05-01 11950275 dpl:Item1 2024-04-30 11950275 dpl:Item1 2022-05-01 11950275 dpl:Item1 2023-04-30 iso4217:GBP xbrli:shares xbrli:pure
Registered Number: 11950275


 

 

 

APOLLO MEDICINES LIMITED


Unaudited Financial Statements
 


Period of accounts

Start date: 01 May 2023

End date: 30 April 2024
Director Taseen Mohammad
Registered Number 11950275
Registered Office 178A MOUNTSTEVEN AVENUE
Peterborough
CAMBRIDGESHIRE
PE4 6HN
Accountants ROGER CARNE ACCOUNTANTS
118 Cobden Avenue
PETERBOROUGH
PE1 2NU
1
Director's report and financial statements
The director presents his/her/their annual report and the financial statements for the year ended 30 April 2024.
Principal activities
Principal activity of the company during the financial year was offering pharmaceutical services.
Director
The director who served the company throughout the year was as follows:
Taseen Mohammad
Statement of director's responsibilities
The director is responsible for preparing the directors' report and the financial statements in accordance with applicable law and regulations and in accordance with United Kingdom Generally Accepted Accounting Practice.
Company law requires the director to prepare financial statements for each financial year. Under that law the director has elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the director must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and the profit or loss of the company for that period.
In preparing these financial statements, the director is required to :
  • select suitable accounting policies and then apply them consistently
  • make judgements and accounting estimates that are reasonable and prudent
  • state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements and
  • prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.
The director is responsible for keeping adequate accounting records that are sufficient to show and explain the company’s transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. The director is also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
The director is responsible for the maintenance and integrity of the corporate and financial information included on the company's website. Legislation in the United Kingdom, governing the preparation and dissemination of financial statements, may differ from legislation in other jurisdictions

On behalf of the board.


----------------------------------
Taseen Mohammad
Director

Date approved: 28 January 2025
2
Accountants report
You consider that the company is exempt from an audit for the year ended 30 April 2024 . You have acknowledged, on the balance sheet, your responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts. These responsibilities include preparing accounts that give a true and fair view of the state of affairs of the company at the end of the financial year and of its profit or loss for the financial year.
In accordance with your instructions, we have prepared the accounts which comprise the Profit and Loss Account, the Statement of Comprehensive Income, the Balance Sheet, the Statement of Changes in Equity and the related notes from the accounting records of the company and on the basis of information and explanations you have given to us.
We have not carried out an audit or any other review, and consequently we do not express any opinion on these accounts.
Financial Analysis of Apollo Medicine:

As the accountant for Apollo Medicine, I have conducted a comprehensive financial analysis of our business operations, focusing on our growth trajectory as a pharmacy and our potential for further expansion in both the pharmacy and retail markets.

Market Growth and Government Initiatives:

The pharmacy industry is experiencing significant growth, driven by several factors including increased healthcare awareness, aging populations, and expanded government initiatives. Notably, the government has granted pharmacies extra responsibilities, allowing them to play a more integral role in healthcare delivery. This regulatory shift has created new revenue streams and opportunities for pharmacies to expand their service offerings, contributing to the overall growth of the market.

Positive Turnover Trend:

Since our inception, Apollo Medicine has demonstrated a consistently positive turnover trend, indicative of our strong performance and growing market presence. In our inaugural year ending 2022, our sales amounted to £595,620. This figure saw a substantial increase to £1,035,069 in 2023, highlighting our rapid growth and the increasing demand for our services. Currently, our turnover stands at £1,110,411, reflecting continued momentum and customer trust in our brand.

Potential for Further Growth:

The financial data indicates that Apollo Medicine is well-positioned for further growth and expansion. Our consistent year-over-year revenue growth underscores the effectiveness of our business strategies and the strength of our market position. Moreover, the growing demand for pharmacy services, coupled with the synergies between our pharmacy and retail divisions, present numerous opportunities for revenue diversification and market penetration.

Future Outlook:

Looking ahead, Apollo Medicine is poised for a promising future in both the pharmacy and retail markets. The favourable regulatory environment, coupled with our track record of growth and profitability, positions us as a leader in the healthcare sector. By leveraging our strengths, capitalizing on market trends, and continuing to innovate, we are well-equipped to seize opportunities for further expansion and solidify our position as a trusted healthcare provider in our community.

In conclusion, the financial analysis demonstrates that Apollo Medicine is on a trajectory of sustained growth and success. With a strong foundation, a growing market, and a commitment to excellence, we are confident in our ability to achieve continued growth and deliver value to our customers and stakeholders in the years to come.






























































....................................................

ROGER CARNE ACCOUNTANTS

118 Cobden Avenue
PETERBOROUGH
PE1 2NU
28 January 2025
3
 
 
Notes
 
30/04/2024
£
  30/04/2023
£
Fixed assets      
Intangible fixed assets 3 422,258    422,258 
Tangible fixed assets 4 213,662    218,546 
635,920    640,804 
Current assets      
Stocks 5 15,000    15,000 
Debtors 6 290,719    86,871 
Cash at bank and in hand 110,379    302,931 
416,098    404,802 
Creditors: amount falling due within one year 7 (134,811)   (216,824)
Net current assets 281,287    187,978 
 
Total assets less current liabilities 917,207    828,782 
Creditors: amount falling due after more than one year 8 (379,002)   (462,665)
Net assets 538,205    366,117 
 

Capital and reserves
     
Profit and loss account 538,205    366,117 
Shareholders' funds 538,205    366,117 
 


For the year ended 30 April 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:
  1. The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476.
  2. The director acknowledges their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. In accordance with Section 444 of the Companies Act 2006, the income statement has not been delivered to the Registrar of Companies.
The financial statements were approved by the director on 28 January 2025 and were signed by:


-------------------------------
Taseen Mohammad
Director
4
  Retained Earnings   Total
£ £
At 01 May 2022 195,324  195,324 
Profit for the year 170,793  170,793 
Total comprehensive income for the year 170,793  170,793 
Total investments by and distributions to owners
At 30 April 2023 366,117  366,117 
At 01 May 2023 371,228  371,228 
Profit for the year 166,977  166,977 
Total comprehensive income for the year 166,977  166,977 
Total investments by and distributions to owners
At 30 April 2024 538,205  538,205 
5
General Information
APOLLO MEDICINES LIMITED is a private company, limited by shares, registered in , registration number 11950275, registration address 178A MOUNTSTEVEN AVENUE, Peterborough, CAMBRIDGESHIRE, PE4 6HN.

The presentation currency is £ sterling.
1.

Accounting policies

Significant accounting policies
Statement of compliance
These financial statements have been prepared in compliance with FRS 102 – The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006.
Basis of preparation
The financial statements have been prepared under the historical cost convention as modified by the revaluation of land and buildings and certain financial instruments measured at fair value in accordance with the accounting policies.
The financial statements are prepared in sterling which is the functional currency of the company.
Turnover
Turnover comprises the invoiced value of goods and services supplied by the company, net of Value Added Tax and trade discounts.
Website cost
Planning and operating costs for the company's website are charged to the income statement as incurred.
Intangible assets
Intangible assets (including purchased goodwill and patents) are amortised at rates calculated to write off the assets on a straight line basis over their estimated useful economic lives. Impairment of intangible assets is only reviewed where circumstances indicate that the carrying value of an asset may not be fully recoverable.
Goodwill
Acquired goodwill is stated at cost less amortisation. Amortisation is calculated on a straight line basis over the estimated expected useful economic life of the goodwill of years.
Tangible fixed assets
Tangible fixed assets, other than freehold land, are stated at cost or valuation less depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost or valuation of fixed assets, less their estimated residual value, over their expected useful lives on the following basis:
Land and Buildings 0 Straight Line
Plant and Machinery 20 Reducing Balance
Motor Vehicles 20 Reducing Balance
Fixtures and Fittings 20 Reducing Balance
Computer Equipment 25 Reducing Balance
Assets on finance lease and hire purchase
Assets held under finance lease or hire purchase contracts i.e. those contracts where substantially all the risks and rewards of ownership have passed to the company, are included in the appropriate category of tangible fixed assets and depreciated over the shorter of the lease term and their estimated expected useful lives.
Future obligations under such contracts are included in creditors net of the finance charge allocated to future periods.
Stocks
Stocks are valued at the lower of cost and net realisable value after making due allowance for obsolete and slow moving items. Cost includes all direct costs and an appropriate proportion of fixed and variable overheads.
2.

Average number of employees

Average number of employees during the year was 6 (2023 : 0).
3.

Intangible fixed assets

Cost Goodwill   Total
  £   £
At 01 May 2023 422,258    422,258 
Additions  
Disposals  
At 30 April 2024 422,258    422,258 
Net book values
At 30 April 2024 422,258    422,258 
At 30 April 2023 422,258    422,258 


4.

Tangible fixed assets

Cost or valuation Plant and Machinery   Motor Vehicles   Fixtures and Fittings   Computer Equipment   Land and Buildings   Total
  £   £   £   £   £   £
At 01 May 2023 2,000    65,530    5,000    2,080    146,726    221,336 
Additions     15,000    874      15,874 
Disposals          
At 30 April 2024 2,000    65,530    20,000    2,954    146,726    237,210 
Depreciation
At 01 May 2023 400    1,148    1,000    152      2,700 
Charge for year 639    17,519    1,598    1,092      20,848 
On disposals          
At 30 April 2024 1,039    18,667    2,598    1,244      23,548 
Net book values
Closing balance as at 30 April 2024 961    46,863    17,402    1,710    146,726    213,662 
Opening balance as at 01 May 2023 1,600    64,382    4,000    1,838    146,726    218,546 

The net book value of Land and Buildings includes £ 146,726 (2023 £146,726) in respect of assets leased under finance leases or hire purchase contracts.

5.

Stocks

30/04/2024
£
  30/04/2023
£
Stocks 15,000    15,000 
15,000    15,000 

6.

Debtors: amounts falling due within one year

30/04/2024
£
  30/04/2023
£
Trade Debtors 294,801    78,177 
Advance Received (15,326)   (15,223)
VAT 27,704    23,917 
307,179    86,871 

6.

Debtors: amounts falling due after one year

30/04/2024
£
  30/04/2023
£
Directors Loan Accounts (16,460)  
(16,460)  

7.

Creditors: amount falling due within one year

30/04/2024
£
  30/04/2023
£
Trade Creditors 91,289    196,289 
Corporation Tax 56,711    30,075 
Advance Paid (41,780)   (22,676)
Other Creditors   (1)
Wages & Salaries Control Account 28,591    13,137 
134,811    216,824 

8.

Creditors: amount falling due after more than one year

30/04/2024
£
  30/04/2023
£
WESLEYAN BANK LOAN (2,774)   215,448 
HMRC Arears 4    4 
Directors' Loan Accounts 381,772    247,213 
379,002    462,665 

9.

Share Capital

Allotted, called up and fully paid
30/04/2024
£
  30/04/2023
£
0 Class A share of £0.00 each  
 

6